Cargando…

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian, Fu, Minyang, Wang, Manni, Wan, Dandan, Wei, Yuquan, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931585/
https://www.ncbi.nlm.nih.gov/pubmed/35303904
http://dx.doi.org/10.1186/s13045-022-01247-x
_version_ 1784671297009090560
author Liu, Jian
Fu, Minyang
Wang, Manni
Wan, Dandan
Wei, Yuquan
Wei, Xiawei
author_facet Liu, Jian
Fu, Minyang
Wang, Manni
Wan, Dandan
Wei, Yuquan
Wei, Xiawei
author_sort Liu, Jian
collection PubMed
description Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor antigens, which could be delivered in the form of whole cells, peptides, nucleic acids, etc. Ideal cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. In this review, we introduced the working mechanism of cancer vaccines and summarized four platforms for cancer vaccine development. We also highlighted the clinical research progress of the cancer vaccines, especially focusing on their clinical application and therapeutic efficacy, which might hopefully facilitate the future design of the cancer vaccine.
format Online
Article
Text
id pubmed-8931585
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89315852022-03-18 Cancer vaccines as promising immuno-therapeutics: platforms and current progress Liu, Jian Fu, Minyang Wang, Manni Wan, Dandan Wei, Yuquan Wei, Xiawei J Hematol Oncol Review Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor antigens, which could be delivered in the form of whole cells, peptides, nucleic acids, etc. Ideal cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. In this review, we introduced the working mechanism of cancer vaccines and summarized four platforms for cancer vaccine development. We also highlighted the clinical research progress of the cancer vaccines, especially focusing on their clinical application and therapeutic efficacy, which might hopefully facilitate the future design of the cancer vaccine. BioMed Central 2022-03-18 /pmc/articles/PMC8931585/ /pubmed/35303904 http://dx.doi.org/10.1186/s13045-022-01247-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Jian
Fu, Minyang
Wang, Manni
Wan, Dandan
Wei, Yuquan
Wei, Xiawei
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title_full Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title_fullStr Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title_full_unstemmed Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title_short Cancer vaccines as promising immuno-therapeutics: platforms and current progress
title_sort cancer vaccines as promising immuno-therapeutics: platforms and current progress
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931585/
https://www.ncbi.nlm.nih.gov/pubmed/35303904
http://dx.doi.org/10.1186/s13045-022-01247-x
work_keys_str_mv AT liujian cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress
AT fuminyang cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress
AT wangmanni cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress
AT wandandan cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress
AT weiyuquan cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress
AT weixiawei cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress